A unique platform to test Oncolytic Viruses against Lung Cancer
Oncolytic virotherapy is an innovative treatment modality which uses replication competent viruses to destroy cancers. A number of oncolytic strategies are rapidly advancing toward clinical use with the requirement to test specificity and safety.
Due to its dual composition (healthy and cancerous human tissues) OncoCilAir™ is an ideal in vitro model for the concurrent testing of the efficacy and the specificity of oncolytic viruses against malignant cells and their non-toxicity against healthy tissues, all in a single culture well.
Typical hyperspectral image of a 3D OncoCilAir™ airway microtissue (blue) with tumor nodules (red) after viral infection (green). Coll. V.Kilin and L.Bonacina, Biophotonics lab, UNIGE.
Mode of Inoculation
Thanks to the unique lifespan of OncoCilAir™ (months), single but also repeated administrations of modified viruses can be performed to simulate chronic treatment in patients.
Assessment of Combined Therapies
OncoCilAir™ allows testing oncolytic therapies in combination with standard chemotherapeutics to detect synergistic improvement of tumor control over monotherapy.
Typical OncoCilAir™ endpoints can be measured throughout the treatment:
- Tumor growth
- Cytokines release
- Tissue integrity (TEER)
- Cytotoxicity (LDH, MTT)
- Ciliated cell functionality (CBF)
In addition, standard protein (immunostaining, western blot) and gene (qPCR, arrays) expression analyses, as well as pathway interference through genetic modifications
can be applied to investigate mechanisms of action.
Contract us to evaluate your novel oncolytic virotherapy
To learn more about Oncotheis services, please contact us
Test OncoCilAir™ microtissues in your facility
OncoCilAir™ is a human microtissue-based 3D lung cancer model which incorporates both a functional airway epithelium and developing tumors.
- 100 % human
- Airway + Tumor + Stroma
- Direct fluorescence read-out
- Ready to use
OncoCilAir™ is cultured at the air-liquid interface on PET Transwell® 0.4 µm inserts and can be kept in culture for several months, allowing the concurrent testing of drug efficacy, side-toxicity and tumor recurrence.
Go to Oncicilair™ Product